0000903423-13-000669.txt : 20131125
0000903423-13-000669.hdr.sgml : 20131125
20131125180206
ACCESSION NUMBER: 0000903423-13-000669
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20131025
FILED AS OF DATE: 20131125
DATE AS OF CHANGE: 20131125
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AERIE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001337553
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 203109565
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7020 KIT CREEK ROAD
STREET 2: SUITE 270
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: 919-313-9650
MAIL ADDRESS:
STREET 1: 7020 KIT CREEK ROAD
STREET 2: SUITE 270
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DUYK GEOFFREY M
CENTRAL INDEX KEY: 0001202090
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36152
FILM NUMBER: 131242038
MAIL ADDRESS:
STREET 1: 301 COMMERCE STREET
STREET 2: SUITE 3300
CITY: FORT WORTH
STATE: TX
ZIP: 76102
3/A
1
dyuksaerie_f3a.xml
OWNERSHIP DOCUMENT
X0206
3/A
2013-10-25
2013-10-25
0
0001337553
AERIE PHARMACEUTICALS INC
AERI
0001202090
DUYK GEOFFREY M
C/O TPG GLOBAL, LLC
301 COMMERCE STREET, SUITE 3300
FORT WORTH
TX
76102
1
0
0
0
Stock Option (right to buy)
3.15
Common Stock
28000
D
The stock options ("Options") reported herein were omitted from Dr. Geoffrey M. Duyk's original Form 3. The Options were granted pursuant to the Aerie Pharmaceuticals, Inc. 2005 Stock Option Plan. The shares of Common Stock ("Common Stock"), par value $0.001 per share, of Aerie Pharmaceuticals, Inc. (the "Issuer") subject to the Options will vest in equal monthly installments over the 36 months following the grant. The Options were granted on September 12, 2013 and are exercisable until September 12, 2023.
Dr. Duyk is a TPG Partner. TPG is affiliated with TPG Biotechnology Partners, L.P. and TPG Biotech Reinvest AIV, L.P. (collectively, the "TPG Funds"), which hold shares of Common Stock.
Dr. Duyk disclaims beneficial ownership of all of the securities that are or may be beneficially owned by the TPG Funds or any of their affiliates. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that Dr. Duyk is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer for purposes of Section 16 of the Exchange Act or otherwise.
(4) Ronald Cami is signing on behalf of Dr. Duyk pursuant to the authorization and designation letter dated July 1, 2013, which was previously filed with the Securities and Exchange Commission.
By: Ronald Cami on behalf of Geoffrey M. Duyk (4)
2013-11-25